Q4 2024 |
95 |
$9.36B |
+$291M |
-$239M |
+$52M |
INCY, ONC, ACAD, MDGL, SMMT
|
13F-HR |
2/14/2025, 04:12 PM |
Q3 2024 |
93 |
$9.65B |
+$239M |
-$134M |
+$105M |
BGNE, INCY, ACAD, SMMT, MDGL
|
13F-HR |
11/14/2024, 04:07 PM |
Q2 2024 |
95 |
$7.83B |
+$925M |
-$626M |
+$300M |
INCY, BGNE, ACAD, MDGL, RVMD
|
13F-HR |
8/14/2024, 04:05 PM |
Q1 2024 |
85 |
$7.93B |
+$378M |
-$511M |
-$133M |
INCY, BGNE, ACAD, MDGL, RYTM
|
13F-HR |
5/15/2024, 04:37 PM |
Q4 2023 |
84 |
$8.79B |
+$625M |
-$10.3B |
-$9.68B |
INCY, BGNE, ACAD, MDGL, RYTM
|
13F-HR |
2/14/2024, 05:12 PM |
Q3 2023 |
114 |
$17.3B |
+$187M |
-$318M |
-$130M |
SGEN, BGNE, INCY, ACAD, BMRN
|
13F-HR |
11/14/2023, 04:25 PM |
Q2 2023 |
115 |
$17.3B |
+$437M |
-$522M |
-$85.6M |
SGEN, INCY, BGNE, ACAD, MDGL
|
13F-HR |
8/14/2023, 05:13 PM |
Q1 2023 |
105 |
$18.4B |
+$255M |
-$413M |
-$158M |
SGEN, INCY, BGNE, ACAD, MDGL
|
13F-HR |
5/15/2023, 04:04 PM |
Q4 2022 |
112 |
$16.7B |
+$272M |
-$93.9M |
+$178M |
SGEN, INCY, BGNE, BMRN, ACAD
|
13F-HR |
2/14/2023, 03:06 PM |
Q3 2022 |
112 |
$15.3B |
+$270M |
-$453M |
-$184M |
SGEN, INCY, BGNE, ACAD, BMRN
|
13F-HR |
11/14/2022, 03:06 PM |
Q2 2022 |
117 |
$17.6B |
+$252M |
-$94M |
+$158M |
SGEN, INCY, BGNE, BMRN, ACAD
|
13F-HR |
8/15/2022, 04:56 PM |
Q1 2022 |
117 |
$17.4B |
+$347M |
-$39.3M |
+$308M |
SGEN, INCY, BGNE, ACAD, BMRN
|
13F-HR |
5/16/2022, 04:05 PM |
Q4 2021 |
120 |
$20.6B |
+$386M |
-$152M |
+$234M |
SGEN, BGNE, INCY, KOD, ACAD
|
13F-HR |
2/14/2022, 03:09 PM |
Q3 2021 |
122 |
$22.8B |
+$600M |
-$307M |
+$293M |
SGEN, BGNE, INCY, KOD, ASND
|
13F-HR |
11/15/2021, 03:58 PM |
Q2 2021 |
120 |
$22.8B |
+$488M |
-$972M |
-$485M |
SGEN, BGNE, INCY, KOD, ACAD
|
13F-HR |
8/16/2021, 04:11 PM |
Q1 2021 |
126 |
$23.1B |
+$741M |
-$871M |
-$130M |
SGEN, BGNE, INCY, KOD, ACAD
|
13F-HR |
5/17/2021, 04:03 PM |
Q4 2020 |
125 |
$26.5B |
+$1.16B |
-$578M |
+$577M |
SGEN, BGNE, INCY, ACAD, KOD
|
13F-HR |
2/16/2021, 02:59 PM |
Q3 2020 |
118 |
$25B |
+$10.4B |
-$156M |
+$10.2B |
SGEN, BGNE, INCY, ACAD, ALXN
|
13F-HR |
11/16/2020, 03:00 PM |
Q2 2020 |
114 |
$22.7B |
+$622M |
-$658M |
-$36.1M |
SGENXXXX, INCY, BGNE, ACAD, ALXN
|
13F-HR |
8/14/2020, 04:08 PM |
Q1 2020 |
110 |
$16.2B |
+$318M |
-$78M |
+$240M |
SGENXXXX, INCY, ACAD, BGNE, ALXN
|
13F-HR |
5/15/2020, 04:03 PM |
Q4 2019 |
99 |
$18.8B |
+$689M |
-$335M |
+$354M |
SGENXXXX, INCY, BGNE, ACAD, ALXN
|
13F-HR |
2/14/2020, 03:26 PM |
Q3 2019 |
109 |
$14.7B |
+$343M |
-$114M |
+$229M |
SGENXXXX, INCY, ACAD, BGNE, ALXN
|
13F-HR |
11/14/2019, 03:05 PM |
Q2 2019 |
103 |
$14.7B |
+$308M |
-$543M |
-$235M |
SGENXXXX, INCY, BGNE, ALXN, ACAD
|
13F-HR |
8/14/2019, 04:01 PM |
Q1 2019 |
96 |
$15.6B |
+$258M |
-$218M |
+$40.6M |
SGENXXXX, INCY, BGNE, ALXN, ACAD
|
13F-HR |
5/15/2019, 04:06 PM |
Q4 2018 |
92 |
$12.2B |
+$526M |
-$251M |
+$274M |
SGENXXXX, INCY, BGNE, ALXN, GHDX
|
13F-HR |
2/13/2019, 03:14 PM |
Q3 2018 |
97 |
$15.1B |
+$407M |
-$422M |
-$15.3M |
SGENXXXX, INCY, BGNE, ALXN, GHDX
|
13F-HR |
11/14/2018, 02:50 PM |
Q2 2018 |
118 |
$13.3B |
+$1.49B |
-$101M |
+$1.39B |
SGENXXXX, INCY, BGNE, ALXN, BMRN
|
13F-HR |
8/14/2018, 03:48 PM |
Q1 2018 |
113 |
$11.8B |
+$818M |
-$196M |
+$622M |
INCY, SGENXXXX, BGNE, ALXN, BMRN
|
13F-HR |
5/15/2018, 03:47 PM |
Q4 2017 |
122 |
$11.5B |
+$716M |
-$257M |
+$459M |
INCY, SGENXXXX, ALXN, ACAD, BMRN
|
13F-HR |
2/14/2018, 02:49 PM |
Q3 2017 |
121 |
$12.3B |
+$271M |
-$86.5M |
+$185M |
INCY, SGENXXXX, ALXN, ACAD, BMRN
|
13F-HR |
11/14/2017, 02:45 PM |
Q2 2017 |
120 |
$11.4B |
+$420M |
-$49.1M |
+$370M |
INCY, SGENXXXX, ALXN, ACAD, BMRN
|
13F-HR |
8/14/2017, 03:48 PM |
Q1 2017 |
118 |
$12.2B |
+$1.55B |
-$39.8M |
+$1.51B |
INCY, SGENXXXX, ACAD, ALXN, GHDX
|
13F-HR |
5/15/2017, 04:00 PM |
Q4 2016 |
131 |
$10.2B |
+$302M |
-$908M |
-$606M |
SGENXXXX, INCY, ALXN, ACAD, GHDX
|
13F-HR |
2/14/2017, 03:13 PM |
Q3 2016 |
131 |
$11B |
+$258M |
-$66M |
+$192M |
SGENXXXX, INCY, ABBV, ACAD, ALXN
|
13F-HR |
11/14/2016, 04:30 PM |
Q2 2016 |
133 |
$9.53B |
+$82.1M |
-$71.5M |
+$10.6M |
INCY, SGENXXXX, ABBV, ACAD, ALXN
|
13F-HR |
8/15/2016, 04:07 PM |
Q1 2016 |
133 |
$9.48B |
+$970M |
-$28.3M |
+$942M |
INCY, SGENXXXX, ALXN, ABBV, ACAD
|
13F-HR |
5/16/2016, 04:12 PM |
Q4 2015 |
132 |
$12.1B |
+$479M |
-$60.7M |
+$419M |
INCY, SGENXXXX, ALXN, ABBV, ACAD
|
13F-HR |
2/16/2016, 03:52 PM |
Q3 2015 |
133 |
$10.8B |
+$1.45B |
-$37.6M |
+$1.41B |
INCY, SGENXXXX, ALXN, ABBV, ACAD
|
13F-HR |
11/16/2015, 03:07 PM |
Q2 2015 |
126 |
$11.4B |
+$2.52B |
-$106M |
+$2.41B |
INCY, SGENXXXX, ALXN, ABBV, ACAD
|
13F-HR |
8/14/2015, 04:19 PM |
Q1 2015 |
130 |
$12B |
+$633M |
-$121M |
+$512M |
PCYC, INCY, GEVA, SGENXXXX, ACAD
|
13F-HR |
5/15/2015, 04:06 PM |
Q4 2014 |
120 |
$9.79B |
+$882M |
-$117M |
+$765M |
PCYC, INCY, GEVA, SGENXXXX, AVNR
|
13F-HR |
2/17/2015, 03:15 PM |
Q3 2014 |
108 |
$7.94B |
+$381M |
-$25.9M |
+$355M |
PCYC, SGENXXXX, GEVA, INCY, ACAD
|
13F-HR |
11/14/2014, 03:51 PM |
Q2 2014 |
106 |
$8.15B |
+$433M |
-$97.1M |
+$336M |
GEVA, PCYC, SGENXXXX, INCY, ACAD
|
13F-HR |
8/14/2014, 04:15 PM |
Q1 2014 |
107 |
$7.87B |
+$656M |
-$153M |
+$503M |
SGENXXXX, GEVA, PCYC, INCY, ACAD
|
13F-HR |
5/15/2014, 04:10 PM |
Q4 2013 |
94 |
$7.09B |
|
|
|
PCYC, SGENXXXX, INCY, GEVA, ACAD
|
13F-HR |
2/14/2014, 03:21 PM |